Stellar presentation David Kirsch, MD, PhD First trial on adding IO in #sarcoma #neoadjuvant #adjuavnt pembrolizumab to preop RT and surgery to >5cm G2/3 pleomorphic sarcoma/DDLiposarcoma improved disease free survival HR 0.57, 2yrDFS 55% to 73%. SARC Australia and New Zealand Sarcoma Association

It’s a pleasure to announce the appointment of Dr. Amar Kishan to Executive Vice Chair for the Department of Radiation Oncology at the David Geffen School of Medicine at UCLA and the UCLA Jonsson Comprehensive Cancer Center.

It’s our pleasure to announce the appointment of Dr. Tania Kaprealian as Vice Chair of Clinical Operations for the Department of Radiation Oncology at the David Geffen School of Medicine at UCLA. #uclahealth #uclaradonc

🚨 Notable-HCC Early stage resectable HCC Neoadjuvant PD-1 blockade plus SBRT -> surgery -> adjuvant ORR 63.2%, 100% DCR!🤩 95% R0 curative resection nature.com/articles/s4146…

A multidisciplinary team at UCLA, including expertise from our Center for East-West Medicine, publishes a contemporary review on managing CW pain that might emerge after local therapy for lung cancer. #lcsm sciencedirect.com/science/articl…

Congrats Ethan Ludmir MD and Chad Tang, MD! This MD Anderson Cancer Center P2 randomized study shows PFS of 10.3 mo vs. 2.5 mo in #PancreasCancer pts with oligometastatic dz treated with metastasis-directed therapy+sys tx vs. sys tx alone. #radonc #endcancer ascopubs.org/doi/10.1200/JC…

Nice to see our AFT-16 trial results published in JAMA Oncology. I think some of the best results seen in #radonc for Stage 3 NSCLC using a neoadjuvant & adjuvant ICB approach with chemoRT I like to call "peri-CRT" (ala "peri-operative"). Helen J. Ross, MD

📣Really important data to consider when interpreting phase III trials #radonc - n=80,000+ patients, 52% permissive of off protocol #radiotherapy - and RT associated with ⬆️ chance of +ve trial Chad Tang, MD Neeraj Agarwal, MD, FASCO Matthias Guckenberger Gerry Hanna Sumanta K. Pal, MD, FASCO Stephen V Liu, MD

Lung cancer awareness IS women’s health awareness

Absolutely brilliant video emphasizing how lung SBRT is truly painless. #radonc Shalini Vinod

Reflecting on a productive #SITC2024 meeting 🙏🏼 ✅ WIN Leadership Institute reunion for brainstorming 🧠 ✅ Sharing our results on myeloid-targeting immunotx with radiotherapy to activate T cells in #sarcoma generating systemic immunity from local-only tx ☢️🤝 📸: Anusha Kalbasi

The phase III KEYNOTE-867 study results will be presented this week at #ESMO24. The difference in G3 toxicity rates is impressive: only 3.7% with lung SBRT compared to 20% when adding Pembro. Also, G3 pneumonitis was 0% with lung SBRT alone. #radonc Salma Jabbour

The phase III CheckMate 73L study results will be presented this week at #ESMO24. Similar to PACIFIC-2, there is no signal of benefit when adding Nivolumab to concurrent CRT for stage III NSCLC. #radonc Solange Peters

Looking forward to this session by Trudy Wu, MD and other UCLA colleagues

One of the best teachers I’ve ever had, grateful to be your friend and colleague. All the best in your next chapter and we’ll miss you at UCLA Minsong Cao

Randomized comparison of SBRT vs RFA for recurrent small HCC (n=166 pts) - Freedom from local progression significantly improved after SBRT: 2a 92.7% vs 75.8%, HR=0.45 ! - No difference in PFS (median 37.6 vs 27.6mo) and OS (2a 97.6% vs 93.9%) ascopubs.org/doi/10.1200/JC…

Can lung cancer patients live with metastatic disease? Yes, they can! 78 yo pt EGFR-mutated oligo-progressive NSCLC received SABR radiotherapy to 22 locations over 11 years while on EGFR-targeted TX. Outstanding quality of life minimal side effects, NED each time after SABR.

Thank you Julia Rotow MD, for highlighting time toxicity. PLEASE understand that it goes far beyond direct interactions with the healthcare system: 👉 Travel - commuting, fatigue, logistics, etc. 👉 Insurance - appeals, billing nightmares, etc. 👉 Medical management -

Sharing our publication The Lancet Oncology reviewing the NCI–IOTN–SITC–AAI Workshop on Combining Immunotx with Radiotherapy☢️ ✅Strategies to address challenges ✅Optimizing clinical trial design ✅Fostering academic-corporate partnerships My Share Link: authors.elsevier.com/c/1kiL65EIIgPe…

Ablative radiation therapy effectively controlled tumors and provided favorable 2-year survival rates in patients with resectable pancreatic cancer who could not undergo surgery. ja.ma/4lxAyjx Eileen M O’Reilly John Cuaron